

# Oliver Zivanovic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7805871/publications.pdf>

Version: 2024-02-01

97  
papers

2,947  
citations

172207

29  
h-index

182168

51  
g-index

99  
all docs

99  
docs citations

99  
times ranked

4069  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100940.	0.3	1
2	Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100926.	0.3	10
3	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100154.	1.0	2
4	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	0.6	9
5	Risk factors for financial toxicity in patients with gynecologic cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 817.e1-817.e9.	0.7	20
6	Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 159-164.	1.2	10
7	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2022-003430.	1.2	5
8	Updates to the Literature on Anastomotic Leaks After Rectosigmoid Resection for Gynecologic Malignancies. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
9	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2021, 160, 51-55.	0.6	2
10	Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. <i>Gynecologic Oncology</i> , 2021, 160, 438-444.	0.6	9
11	The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. <i>Gynecologic Oncology</i> , 2021, 160, 99-105.	0.6	10
12	Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1189-1202.	2.0	7
13	Why was GOG-0213 a negative trial?. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e19.	1.0	7
14	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	0.6	2
15	Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S137-S143.	0.6	4
16	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 687-692.	0.6	14
17	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2021, 163, 36-40.	0.6	18
18	Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm. <i>Gynecologic Oncology</i> , 2021, 162, 262-267.	0.6	12

#	ARTICLE	IF	CITATIONS
19	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. <i>Gynecologic Oncology</i> , 2021, 162, 345-352.	0.6	8
20	Quaternary and beyond cytoreduction: An updated and expanded analysis. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100851.	0.3	1
21	Digital Technical and Informal Resources of Breast Cancer Patients From 2012 to 2020: Questionnaire-Based Longitudinal Trend Study. <i>JMIR Cancer</i> , 2021, 7, e20964.	0.9	4
22	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 222-231.	1.2	2
23	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	0
24	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	3
25	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. <i>Gynecologic Oncology</i> , 2020, 156, 591-597.	0.6	54
26	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. <i>Gynecologic Oncology</i> , 2020, 156, 147-153.	0.6	61
27	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	0.6	16
28	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. <i>Gynecologic Oncology</i> , 2020, 159, 66-71.	0.6	12
29	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1162-1168.	1.2	6
30	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1915-1921.	1.2	29
31	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. <i>Gynecologic Oncology</i> , 2020, 159, 187-194.	0.6	12
32	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. <i>Gynecologic Oncology</i> , 2020, 158, 608-613.	0.6	23
33	Evolution and outcomes of sentinel lymph node mapping in vulvar cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 383-386.	1.2	25
34	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2020, 158, 397-401.	0.6	7
35	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3772-3780.	0.7	16
36	IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 670-683.	1.2	18

#	ARTICLE	IF	CITATIONS
37	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1554-1561.	1.2	7
38	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	1.0	22
39	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1183-1188.	1.2	4
40	Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 505-515.	0.6	11
41	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2019, 154, 333-337.	0.6	14
42	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. <i>Gynecologic Oncology</i> , 2019, 154, 77-82.	0.6	24
43	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. <i>Gynecologic Oncology</i> , 2019, 154, 144-149.	0.6	24
44	Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program. <i>JAMA Oncology</i> , 2019, 5, 570.	3.4	9
45	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	7
46	Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1377-1380.	1.2	7
47	Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. <i>Cancer Medicine</i> , 2018, 7, 2280-2287.	1.3	21
48	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	0.8	61
49	It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 555-561.	0.6	29
50	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 433-437.	0.6	16
51	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. <i>Gynecologic Oncology</i> , 2018, 150, 44-49.	0.6	30
52	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. <i>Gynecologic Oncology</i> , 2018, 151, 24-31.	0.6	64
53	Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. <i>International Journal of Hyperthermia</i> , 2017, 33, 548-553.	1.1	41
54	A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 230-235.	0.6	43

#	ARTICLE	IF	CITATIONS
55	Optimal primary management of bulky stage IIIc ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	0.6	55
56	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 122-129.	0.6	21
57	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 27-31.	0.6	95
58	Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. <i>Gynecologic Oncology</i> , 2017, 146, 263-267.	0.6	33
59	Risk-reducing salpingectomy: Let us be opportunistic. <i>Cancer</i> , 2017, 123, 1714-1720.	2.0	31
60	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 371-374.	0.6	7
61	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017, 170, 927-938.e20.	13.5	368
62	Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 262-266.	0.6	43
63	Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. <i>Gynecologic Oncology</i> , 2017, 147, 115-119.	0.6	31
64	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. <i>Gynecologic Oncology</i> , 2016, 142, 13-18.	0.6	2
65	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. <i>Annals of Surgical Oncology</i> , 2016, 23, 2522-2528.	0.7	69
66	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 143, 496-503.	0.6	12
67	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 447-456.	1.1	16
68	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. <i>Gynecologic Oncology</i> , 2016, 142, 217-224.	0.6	42
69	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 140, 436-442.	0.6	97
70	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2192-2198.	0.7	43
71	Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 383-386.	0.6	10
72	Is It Time to Centralize Ovarian Cancer Care in the United States?. <i>Annals of Surgical Oncology</i> , 2016, 23, 989-993.	0.7	44

#	ARTICLE	IF	CITATIONS
73	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. <i>Annals of Surgical Oncology</i> , 2016, 23, 196-202.	0.7	86
74	Early diagnosis of genital mucosal melanoma: how good are our dermoscopic criteria?. <i>Dermatology Practical and Conceptual</i> , 2016, 6, 43-46.	0.5	21
75	Fertility-sparing surgery in stage IA2 cervical cancer: Associated factors and long-term survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17012-e17012.	0.8	0
76	Stage IA2 cervical cancer: Long-term outcomes with less radical as opposed to more radical surgical management.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17011-e17011.	0.8	1
77	Long-term oncologic outcomes of fertility-sparing surgery in young women with stage IB1 cervical cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17010-e17010.	0.8	0
78	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5525-5525.	0.8	0
79	HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2015, 136, 699-708.	2.3	75
80	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 246-251.	0.6	71
81	TabPRO trial: Tablet-based real-time detection of patient-reported outcomes during adjuvant outpatient chemotherapy for breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS9640-TPS9640.	0.8	0
82	Neoadjuvant chemotherapy (NACT) selection for advanced stage ovarian cancer (AOC) at a comprehensive cancer center.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16579-e16579.	0.8	0
83	Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 299-302.	0.6	14
84	A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 468-472.	0.6	10
85	Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 25-30.	0.6	59
86	A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. <i>Cancer</i> , 2012, 118, 660-669.	2.0	126
87	The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. <i>Gynecologic Oncology</i> , 2010, 116, 351-357.	0.6	61
88	Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. <i>Journal of Clinical Oncology</i> , 2009, 27, 2066-2072.	0.8	119
89	Sentinel Lymph Node Biopsy in the Management of Vulvar Carcinoma, Cervical Cancer, and Endometrial Cancer. <i>Oncologist</i> , 2009, 14, 695-705.	1.9	36
90	Advanced cytoreductive surgery: American perspective. <i>Gynecologic Oncology</i> , 2009, 114, S3-S9.	0.6	36

#	ARTICLE	IF	CITATIONS
91	Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 115, 209-214.	0.6	27
92	Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment. <i>Cancer</i> , 2008, 112, 2690-2697.	2.0	4
93	The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2008, 108, 287-292.	0.6	109
94	Retroperitoneal lymph node dissection (RPLND). <i>Gynecologic Oncology</i> , 2008, 111, S66-S69.	0.6	10
95	Treatment patterns of FIGO Stage IB2 cervical cancer: A single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. <i>Gynecologic Oncology</i> , 2008, 111, 265-270.	0.6	36
96	The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. <i>Gynecologic Oncology</i> , 2008, 111, 431-437.	0.6	153
97	Surgical resection and reconstruction for advanced and recurrent gynecologic malignancies. <i>Expert Review of Obstetrics and Gynecology</i> , 2008, 3, 677-690.	0.4	1